A Phase Ii, Randomized Trial Of Standard Of Care With Or Without Midostaurin To Prevent Relapse Following Allogeneic Stem Cell Transplantation In Patients With Flt3-Itd Mutated Acute Myeloid Leukemia.
JOURNAL OF CLINICAL ONCOLOGY（2015）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要